A randomised controlled trial comparing deep neuromuscular blockade reversed with sugammadex with moderate neuromuscular block reversed with neostigmine
S Boggett, R Chahal, J Griffiths, J Lin, D Wang, Z Williams, B Riedel, A Bowyer, A Royse, C Royse
Anaesthesia | WILEY | Published : 2020
This trial was registered at clinicaltrials.gov (NCT03034577). We thank the anaesthetists, endoscopists and nursing staff at the Royal Melbourne Hospital, Royal Women's Hospital, Peter MacCallum Cancer Centre and Northpark Private Hospitals for their assistance with the conduct of the trial. CR is Australian Director, Outcomes Research Consortium, Cleveland Clinic, Cleveland, OH, USA. CR is a founder of the Postoperative Quality of Recovery scale and a Director of PostopQRS Limited. The study was funded by Merck and Co., which manufactures sugammadex. No other external funding or competing interests declared.